Psoriasis is a chronic inflammatory disease with an established genetic background. The
HLA-Cw* 06 allele and different polymorphisms in genes involved in inflammatory …

Severe acute respiratory syndrome coranovirus-2 (SARS-CoV-2) infection has become an
important health-care issue worldwide. The coronavirus disease 2019 (COVID-19) has also …

Objective: Our pharmacogenomic study evaluated the influence of the presence/absence of
genetic variants of psoriasis-risk loci on the clinical response to secukinumab. Differences in …

A number of randomized controlled trials and real‐world studies have demonstrated the
effectiveness and safety of secukinumab in the treatment of moderate to severe psoriasis …

Introduction Interleukin 17 is a proinflammatory cytokine considered to play a significant role
in the immunopathogenesis of many chronic immune-mediated disorders. Interleukin 17 …

Background Psoriasis patients carry an increased risk for associated comorbidities.
Dermatologists have to be aware of the effects of systemic treatments not only on psoriasis …

The application of interleukin-17 (IL-17) inhibitors, including secukinumab, ixekizumab,
brodalumab, and bimekizumab, are associated with elevated risk of candidiasis. These …

Background Multiple biologics for psoriasis exist, and interleukin (IL) 17 inhibitors are
among those with the best efficacy. However, switching treatment is often required at some …

Since psoriasis (PsO) is a chronic inflammatory disease, patients may experience a drug
failure also with very effective drugs (ie, secukinumab) and, consequently, dermatologists …

As aberrant IL-17 signaling plays a critical role in the pathogenesis of psoriasis, biologic
agents targeting this pathway have become an important weapon against this disease …